

PRESS RELEASE

## FluoSphera and Sciomics Launch Integrated Safety and Efficacy Profiling Service for Preclinical Drug Development

One workflow, one experiment: human 3D multi-tissue biology plus high-content proteomics show not only whether a compound is efficacious or toxic, but in which tissue, through which pathway, and with which candidate biomarkers.

Geneva, Switzerland, and Neckargemünd, Germany, September 16th 2026

FluoSphera and Sciomics today launched a joint translational profiling service that combines FluoSphera's human-relevant 3D multi-tissue platform with Sciomics' high-content proteomic profiling. In a single experiment, pharma and biotech teams can assess efficacy, liver-dependent metabolism and organ-specific toxicity – and identify the proteins, pathways and candidate translational biomarkers behind them.

Late-stage safety failures remain one of the costliest problems in drug development. Conventional in vitro models test tissues in isolation and rely largely on terminal endpoints such as cell viability. They therefore miss organ-to-organ interactions, liver-mediated activation or inactivation, simultaneous effects on healthy and diseased tissue, and early sublethal molecular responses.

The joint offering addresses this by design rather than by adding proteomics as a downstream characterisation step: biology and protein analysis are planned together from the outset. FluoSphera brings standardized human 3D tissue models in which tumor and healthy organ tissues are exposed simultaneously under identical conditions, with liver-dependent metabolism and bioactivation built in. Sciomics profiles cellular and secreted proteins across those tissues and adds pathway analysis, biomarker discovery and translational interpretation.

“In vitro work has usually forced a choice between physiological relevance and molecular depth. Combining human multi-tissue biology with comprehensive protein profiling removes that trade-off – and it does so before a compound reaches costly late-stage development.”

Gregory Segala, CSO, FluoSphera

The workflow has already been successfully demonstrated in a proof-of-concept study conducted in partnership with AbbVie, with the results now being prepared for publication. The study combined human colorectal tumor spheroids, liver spheroids and human cardiac tissue in one multi-tissue system. Capecitabine was fully converted only in liver-containing conditions, allowing efficacy and toxicity

responses to be linked directly to molecular changes. Proteomic profiling of lysates and secreted proteins identified distinct protein panels for tumor efficacy, cardiotoxicity and hepatotoxicity, mapping to DNA damage response, cell-cycle regulation, apoptosis and tissue-specific stress signalling - all from a single experiment.

“Developers need to know not only whether a compound triggers a biological response, but why it occurs, how it develops, and which biomarkers predict it. Together we deliver that in one integrated study, with richer and more actionable data than either approach alone.”

Christoph Schröder, CEO, Sciomics

The service is available immediately to biotechnology and pharmaceutical organisations seeking more predictive, mechanism-based preclinical safety and efficacy assessment. For more information about the collaboration and its applications, visit [translational-safety.com](https://translational-safety.com).

## ABOUT FLUOSPHERA

FluoSphera is a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety. Its proprietary technology combines multiple encapsulated 3D tissue models within a single experimental system, enabling physiologically relevant tissue interactions to be studied. By generating more predictive translational data earlier in development, FluoSphera helps pharmaceutical and biotechnology companies faster select for the most promising, de-risked candidates, investigate mechanisms of action, identify safety risks, and reduce reliance on animal testing.

### Press contact

Dr. Gregory Segala, CSO  
FluoSphera SA, c/o Fongit, Route de la Galaise 34  
1228 Plan-les-Ouates, Switzerland  
Phone +41 22 379 65 83  
Email: [press@fluosphera.com](mailto:press@fluosphera.com)  
Web: [www.fluosphera.com](http://www.fluosphera.com)

## ABOUT SCIOMICS

Sciomics is a proteomics-focused biotechnology company that provides pharma and biotech partners with decision-ready data to de-risk R&D programs and accelerate development. Its high-content affinity proteomics platform supports target and pathway validation, preclinical development, translational biomarker discovery, patient stratification, and therapy response prediction across the full R&D pipeline. Sciomics offers contract research and collaborative R&D across all disease areas, and develops its own multi-protein biomarker panels – most advanced in Acute Kidney Injury (AKI), validated in large patient cohorts.

### Press contact

Dr. Christoph Schröder, CEO  
Sciomics GmbH, Karl-Landsteiner Str. 6  
69151 Neckargemünd, Germany  
Phone +49 6223 9689 500  
Email: [presse@sciomics.de](mailto:presse@sciomics.de)  
Web: [www.sciomics.de](http://www.sciomics.de)